Evaluation of genetically engineered herpes simplex viruses as oncolytic agents for human malignant brain tumors

Cancer Research

Volumn 57, Issue 8, 1997, Pages 1502-1509

  Andreansky, Samita ^a   Soroceanu, Liliana ^a   Flotte, Edward R ^a   Chou, Joany ^b   Markert, James M ^a   Gillespie, G Yancey ^a,c   Roizman, Bernard ^b   Whitley, Richard J ^a  

^a UNIVERSITY OF ALABAMA SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF CHICAGO   (United States)

^c UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC ACTIVITY; ARTICLE; BRAIN CANCER; CYTOTOXICITY; GENE DELETION; GENE TARGETING; GENE THERAPY; GENETIC ENGINEERING; HERPES SIMPLEX VIRUS; HUMAN; HUMAN CELL; NONHUMAN; PRIORITY JOURNAL; VIRUS MUTATION; VIRUS VIRULENCE;

ACYCLOVIR; ANIMALS; ANTIVIRAL AGENTS; ASTROCYTES; BRAIN NEOPLASMS; CERCOPITHECUS AETHIOPS; CYTOPATHOGENIC EFFECT, VIRAL; DNA, VIRAL; GENETIC ENGINEERING; GLIOMA; HERPESVIRUS 1, HUMAN; HUMANS; IMMEDIATE-EARLY PROTEINS; MICE; MICE, SCID; TRANSPLANTATION, HETEROLOGOUS; VERO CELLS; VIRUS REPLICATION;

EID: 0030897659     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (21)

1. Boviatsis, E. J., Chase, M., Wei, M. X., Tamiya, T., Hurford, R. K., Jr., Kowall, N. W., Tepper, R. I., Breakefield, X. O., and Chiocca, E. A. Gene transfer into experimental brain tumors mediated by adenovirus, herpes simplex virus, and retrovirus vectors. Hum. Gene Ther., 5: 183-191, 1994.
2. Roizman, B., Whitley, R. J., and Lopez, C. The Human Herpesviruses, pp. 1-433, New York: Academic Press, 1992.
3. 134.5 gene function, which blocks the host response to infection, maps in the homologous domain of the genes expressed during growth arrest and DNA damage. Proc. Natl. Acad. Sci. USA, 91: 5427-5251, 1994.
4. 134.5 gene of herpes simplex virus. J. Virol., 68: 8304-8311, 1994.
5. 134.5 gene of herpes simplex virus 1 precludes neuroblastoma cells from triggering total shutoff of protein synthesis characteristic of programmed cell death in neuronal cells. Proc. Natl. Acad. Sci. USA, 89: 3266-3270, 1992.
6. - mutants of herpes simplex virus 1. Proc. Natl. Acad. Sci. USA, 92: 10516-10520, 1995.
7. 134.5, a gene nonessential for growth in culture. Science (Washington DC), 250: 1262-1266, 1990.
8. Bolovan, C. A., Sawtell, N. M., and Thompson, R. L. ICP34.5 mutants of herpes simplex virus type 1 strain 17syn+ are attenuated for neurovirulence in mice and for replication in confluent primary mouse embryo cell cultures. J. Virol., 68: 48-55, 1994.
9. Markert, J. M., Malick, A., Coen, D. M., and Martuza, R. L. Reduction and elimination of encephalitis in an experimental glioma therapy model with attenuated herpes simplex mutants that retain susceptibility to acyclovir. Neurosurgery, 32: 597-603, 1993.
10. Chambers, R., Gillespie, G. Y., Soroceanu, L., Andreansky, S., Chatterjee, S., Chou, J., Roizman, B., and Whitley, R. J. Comparison of genetically engineered herpes simplex viruses for the treatment of brain tumors in a scid mouse model of human malignant glioma. Proc. Natl. Acad. Sci. USA, 92: 1411-1415, 1995.
11. Loeffel, S. L., Gillespie, G. Y., Mirmiran, S. A., Miller, E. W., Golden, P., Askin, F. B., and Siegal, G. S. Cellular immunolocalization of S-100 protein specific monoclones within fixed human tissue sections. Arch. Pathol. Lab. Med., 709: 117-122, 1985.
12. Lyon, E., and Gillespie, G. Y. Monoclonal antibodies to glioma-derived growth factor(s). Hybridoma, 13: 15-20, 1994.
13. Tsai, J-C., Goldman, C. K., and Gillespie, G. Y. Vascular endothelial growth factor in human glioma cell lines: induced secretion by EGF, PDGF-BB and bFGF. J. Neurosurg., 82: 864-873, 1995.
14. Gillespie, G. Y., Van Wyk, J. J., Underwood, L. E., Svoboda, M., and Russell, W. E. Derivation of monoclonal antibodies to human somatomedin-c/IGF-I. Methods Enzymol., 146: 207-216, 1987.
15. Neff, M. J., and Enders, J. F. Poliovirus replication and cytopathogenicity in monolayer hamster cell cultures fused with p-propiolactone-inactivated Sendai virus. Proc. Soc. Exp. Biol. Med., 727: 260-267, 1963.
16. Towbin, H., Staehlin, T., and Gordon, J. Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: procedure and some applications. Proc. Natl. Acad. Sci. USA, 76: 4350-4354, 1979.
17. Greenwood, F. C., Hunter W. M., and Clover, J. C. The preparation of I-131-labelled human growth hormone of high specific radioactivity. J. Biochem., 89: 114-123, 1963.
18. Markert, J. M., Coen, D. M., Malick, A., Mineta, T., and Martuza, R. L. Expanded spectrum of viral therapy in the treatment of nervous system tumors. J. Neurosurg., 77: 590-594, 1992.
19. Martuza, R. L., Malick, A., Markert, J. M., Ruffner, K. L., and Coen, D. M. Experimental therapy of human glioma by means of a genetically engineered virus mutant. Science (Washington DC), 252: 854-856, 1991.
20. Mineta, T., Rabkin, S. D., and Martuza, R. L. Treatment of malignant gliomas using gancyclovir-hypersensitive, ribonucleotide reductase-deficient herpes simplex virus mutant. Cancer Res., 54: 3963-3966, 1994.
21. 134.5 deletion mutants in rodent models. J. Clin. Invest., 91: 2837-2843, 1993.